Martin Schnierer, Peter Lipták, Peter Hyrdel, Lenka Bubernáková, Rudolf Hyrdel
Although the knowledge about the usage, safety and effectivity of 5-aminosalicylates is considerable, still new studies
are published, that help with the individualization of treatment of patients with IBD. Despite of current recommendations,
new findings have been constantly presented that help optimize long term management of patients and
improve their quality of life. In the next article we would like to present you the results of two studies focused on 5-aminosalicylates,
as the baseline therapy mainly of ulcerative colitis, with focusing on new knowledge about the dosage
of this medication.